MX2016009058A - Compuesto de acido piridilaminoacetico y composicion farmaceutica que contiene aceite de ricino polioxietileno. - Google Patents

Compuesto de acido piridilaminoacetico y composicion farmaceutica que contiene aceite de ricino polioxietileno.

Info

Publication number
MX2016009058A
MX2016009058A MX2016009058A MX2016009058A MX2016009058A MX 2016009058 A MX2016009058 A MX 2016009058A MX 2016009058 A MX2016009058 A MX 2016009058A MX 2016009058 A MX2016009058 A MX 2016009058A MX 2016009058 A MX2016009058 A MX 2016009058A
Authority
MX
Mexico
Prior art keywords
castor oil
pharmaceutical composition
acid compound
polyoxyethylene castor
pyridylaminoacetic acid
Prior art date
Application number
MX2016009058A
Other languages
English (en)
Spanish (es)
Inventor
Endo Yoko
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of MX2016009058A publication Critical patent/MX2016009058A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2016009058A 2014-01-10 2015-01-08 Compuesto de acido piridilaminoacetico y composicion farmaceutica que contiene aceite de ricino polioxietileno. MX2016009058A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014002809 2014-01-10
PCT/JP2015/050333 WO2015105134A1 (ja) 2014-01-10 2015-01-08 ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物

Publications (1)

Publication Number Publication Date
MX2016009058A true MX2016009058A (es) 2016-09-09

Family

ID=53523959

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009058A MX2016009058A (es) 2014-01-10 2015-01-08 Compuesto de acido piridilaminoacetico y composicion farmaceutica que contiene aceite de ricino polioxietileno.

Country Status (19)

Country Link
US (3) US20160317512A1 (enExample)
EP (2) EP3888654B1 (enExample)
JP (5) JP6012775B2 (enExample)
KR (6) KR101858373B1 (enExample)
CN (2) CN105828817B (enExample)
AU (1) AU2015205268B2 (enExample)
BR (1) BR112016015911B1 (enExample)
CA (1) CA2934612C (enExample)
EA (1) EA031723B1 (enExample)
ES (2) ES2953346T3 (enExample)
GE (1) GEP20186916B (enExample)
IL (1) IL246654B (enExample)
MX (1) MX2016009058A (enExample)
MY (1) MY166210A (enExample)
PH (1) PH12016501327B1 (enExample)
SG (1) SG11201605532YA (enExample)
TW (1) TWI612960B (enExample)
UA (1) UA121744C2 (enExample)
WO (1) WO2015105134A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3750541A1 (en) 2014-01-10 2020-12-16 Santen Pharmaceutical Co., Ltd Pharmaceutical preparation containing pyridylaminoacetic acid compound
TWI612960B (zh) * 2014-01-10 2018-02-01 Santen Pharmaceutical Co Ltd 吡啶基胺基乙酸化合物及含聚氧乙烯蓖麻油之醫藥組成物
WO2015105135A1 (ja) * 2014-01-10 2015-07-16 参天製薬株式会社 ピリジルアミノ酢酸化合物含有医薬組成物
ES2950461T3 (es) 2015-07-09 2023-10-10 Santen Pharmaceutical Co Ltd Agente preventivo y/o terapéutico que contiene un compuesto de ácido piridilaminoacético para el tratamiento de una enfermedad que involucra una presión intraocular muy elevada
US20200121652A1 (en) 2017-06-16 2020-04-23 The Doshisha Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent
US11433090B2 (en) 2017-06-16 2022-09-06 The Doshisha mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
US10940144B2 (en) 2017-09-29 2021-03-09 Santen Pharmaceutical Co., Ltd. Drug containing pyridylaminoacetic acid compound
KR20200103041A (ko) 2017-12-21 2020-09-01 산텐 세이야꾸 가부시키가이샤 오미데네팍의 조합
CA3087019A1 (en) * 2017-12-28 2019-07-04 Santen Pharmaceutical Co., Ltd. Pharmaceutical preparation containing pyridyl aminoacetic acid compound
WO2021107033A1 (ja) * 2019-11-29 2021-06-03 千寿製薬株式会社 医薬組成物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
JP3297969B2 (ja) * 1994-12-26 2002-07-02 ライオン株式会社 点眼剤
BR9906597A (pt) * 1998-07-14 2000-07-18 Alcon Lab Inc Produto de prostaglandina
US6235781B1 (en) * 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
US20020009507A1 (en) * 2000-01-19 2002-01-24 Alcon Universal Ltd. Use of polyethoxylated castor oil for the treatment of dry eye
JP2002356420A (ja) * 2001-03-27 2002-12-13 Santen Pharmaceut Co Ltd 安定な水性液剤
DK2264009T3 (en) 2008-03-12 2019-04-15 Ube Industries PYRIDYLAMINE ACEDIC ACID COMPOUND
WO2010113957A1 (ja) * 2009-03-30 2010-10-07 宇部興産株式会社 緑内障の治療又は予防のための医薬組成物
JP2011057633A (ja) * 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬
US20120058983A1 (en) * 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
JP2014019650A (ja) * 2012-07-13 2014-02-03 Santen Pharmaceut Co Ltd スルホンアミド化合物とタフルプロストの組み合わせ
US20140018350A1 (en) * 2012-07-13 2014-01-16 Asahi Glass Co., Ltd. Combination of sulfonamide compound and tafluprost
US9339496B2 (en) * 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
KR102074020B1 (ko) * 2012-07-13 2020-02-05 산텐 세이야꾸 가부시키가이샤 술폰아미드 화합물의 조합
EP3750541A1 (en) * 2014-01-10 2020-12-16 Santen Pharmaceutical Co., Ltd Pharmaceutical preparation containing pyridylaminoacetic acid compound
TWI612960B (zh) * 2014-01-10 2018-02-01 Santen Pharmaceutical Co Ltd 吡啶基胺基乙酸化合物及含聚氧乙烯蓖麻油之醫藥組成物
WO2015105135A1 (ja) * 2014-01-10 2015-07-16 参天製薬株式会社 ピリジルアミノ酢酸化合物含有医薬組成物

Also Published As

Publication number Publication date
KR20240096869A (ko) 2024-06-26
EP3093021A4 (en) 2017-07-26
MY166210A (en) 2018-06-22
PH12016501327A1 (en) 2017-02-06
CA2934612C (en) 2021-09-07
KR102230683B1 (ko) 2021-03-19
KR20200053651A (ko) 2020-05-18
JP7170020B2 (ja) 2022-11-11
US20200113880A1 (en) 2020-04-16
IL246654B (en) 2020-05-31
GEP20186916B (en) 2018-11-12
UA121744C2 (uk) 2020-07-27
CN105828817B (zh) 2019-07-05
PH12016501327B1 (en) 2017-02-06
EP3888654B1 (en) 2023-06-14
JP6449205B2 (ja) 2019-01-09
KR102111157B1 (ko) 2020-05-14
JP2015147762A (ja) 2015-08-20
KR102675685B1 (ko) 2024-06-14
JP6793172B2 (ja) 2020-12-02
EP3888654A1 (en) 2021-10-06
WO2015105134A1 (ja) 2015-07-16
TW201611833A (en) 2016-04-01
CN105828817A (zh) 2016-08-03
CA2934612A1 (en) 2015-07-16
NZ721530A (en) 2021-03-26
BR112016015911B1 (pt) 2022-04-05
JP2017031177A (ja) 2017-02-09
EP3093021A1 (en) 2016-11-16
CN110251516B (zh) 2022-05-03
JP2022189964A (ja) 2022-12-22
KR102458180B1 (ko) 2022-10-21
EP3093021B1 (en) 2021-06-02
JP6012775B2 (ja) 2016-10-25
US20230372316A1 (en) 2023-11-23
JP2019034973A (ja) 2019-03-07
CN110251516A (zh) 2019-09-20
HK1224191A1 (zh) 2017-08-18
US20160317512A1 (en) 2016-11-03
KR20210032547A (ko) 2021-03-24
EA201691139A1 (ru) 2017-02-28
EA031723B1 (ru) 2019-02-28
IL246654A0 (en) 2016-08-31
ES2874547T3 (es) 2021-11-05
BR112016015911A2 (enExample) 2017-08-08
AU2015205268A1 (en) 2016-07-14
KR101858373B1 (ko) 2018-05-15
KR20160100977A (ko) 2016-08-24
JP2021011508A (ja) 2021-02-04
AU2015205268B2 (en) 2019-03-14
TWI612960B (zh) 2018-02-01
ES2953346T3 (es) 2023-11-10
SG11201605532YA (en) 2016-08-30
JP7546027B2 (ja) 2024-09-05
KR20220146691A (ko) 2022-11-01
KR20180050770A (ko) 2018-05-15

Similar Documents

Publication Publication Date Title
MX2016009058A (es) Compuesto de acido piridilaminoacetico y composicion farmaceutica que contiene aceite de ricino polioxietileno.
MX2016009049A (es) Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico.
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
MX2018015625A (es) Compuestos y composiciones para inhibir la actividad de shp2.
MX2021012517A (es) Solucion que comprende nicotina en forma desprotonada y en forma protonada.
TN2016000268A1 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2.
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
MX2015016971A (es) Formulacion que comprende un agente hipolipidemico.
CU24330B1 (es) Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral)
AR102767A1 (es) Inhibidores de ezh2
EP3480186A4 (en) NEW ARYLETE HAND DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREFORE AS AN ACTIVE SUBSTANCE
HK1257171A1 (zh) 間變性淋巴瘤激酶（alk）和絲氨酸富集蛋白激酶 （sppk）的抑制劑及其使用方法
EA201791396A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
AR089457A1 (es) Composicion para el control de plagas
MX2017008072A (es) Formulaciones de un inhibidor de pi3k/mtor para administracion intravenosa.
EA201692045A1 (ru) Производное фенантролинфосфоновой кислоты и способ его получения и применения
EP3459936A4 (en) NEW ARYLETE HAND DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREFORE AS AN ACTIVE SUBSTANCE
EA201791397A1 (ru) СВЯЗАННЫЕ С ГЕТЕРОЦИКЛИЛАМИ ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
UY36160A (es) “3-arilpirazoles herbicidas sustituidos”.
BR112015029378A2 (pt) inibidor de crescimento de broto axilar em tabaco e método para inibição de crescimento de broto axilar em tabaco
AR107164A1 (es) INHIBIDORES DE QUINASA p38
MA41158A (fr) Composition pharmaceutique comprenant un composé d'amide hétérocyclique aromatique contenat de l'azote bicyclique en tant que principe actif
TH169353A (th) สารประกอบแอเซทิดินิลออกซีเฟนิลพิร์โรลิดีน